

Which Export Format should I use?

There are advantages and disadvantages to every BizInt export format. Understanding your client's needs will help you select the best distribution format.



- How will you be distributing your report?** The **HTML** format is ideal for publication on intranets and can include linked records, images, and links to related information. If you are emailing your report, consider using the **Word** or **Acrobat** formats, especially if your report contains images.
- Does the recipient need to view related information** — complete records, related records on publisher websites, full text patents, etc.? The Web, Word, and Acrobat export formats allow you to include a wide range of links.

- Will the recipient be editing or customizing the report?** Most users just want to view the report and follow links to related information. The HTML and Acrobat formats work well for these users. If your clients need to add comments or customize the report, consider using the Word or Excel exports. Or, for "aggressive end-users" consider giving them access to BizInt Smart Charts Viewer.

- Will images be included in the report?** The images in most export formats are a directory of linked images and difficult to include in an email. If your report includes images and you distribute your reports via email, consider using Acrobat or Word. See page 2 for more details.

- Are there copyright limitations to consider when distributing your report?** If you are including the records in your exported report, be aware of the redistribution rights for each publisher's data. BizInt Smart Charts includes a copyright line at the bottom of every exported record.

Telaprevir - Sept 2011		Word - Chart and Records					
	Trial Title	Common Trial ID	Database	Drugs	Sponsor(s)	Brief Summary	
1 Link	VX-950-TIDP24-C219: A Roll Over Trial for Patients in the Control Group of the C216 Study Who Received Telaprevir Placebo	NCT01054573	ClinicalTrials.Gov	Telaprevir/standard treatment	Tibotec BVBA Vertex Pharmaceuticals Incorporated	The purpose of this study is to provide access to telaprevir for patients from the control group in the C216 study, who failed treatment for virologic reasons. Efficacy, safety and tolerability of telaprevir in combination with standard treatment will be evaluated.	
2 Link	An Open-label, Single-arm, Roll-over Trial of Telaprevir in Combination With Pegylated Interferon Alfa and Ribavirin in Subjects From the C216 Trial Who Failed Therapy for Virologic Reasons.	NCT01054573	Adis Clinical Trials Database	Peginterferon-alfa-2a Ribavirin Telaprevir	Johnson & Johnson Pharmaceutical Research & Development, Tibotec Pharmaceuticals, Vertex Pharmaceuticals	This trial will assess the efficacy of telaprevir [Vertex Pharmaceuticals] + peginterferon alfa 2a [Pegasys] + ribavirin [Copegus] in patients with hepatitis C. The primary endpoint is efficacy. This will be assessed at 24 weeks.	
3 Link	An Open-label, Single-arm, Roll-over Trial of Telaprevir in Combination With Pegylated Interferon Alfa-2a (Pegasys) and Ribavirin (Copegus) for Subjects From the Control Group of the VX-950-TIDP24-C216 Trial Who Failed Therapy for Virologic Reasons. Rollover study of VX-950-TIDP24-C216.	NCT01054573	Citeline.TrialTrove	telaprevir, peginterferon alfa-2a (SC) ribavirin, Roche	Johnson & Johnson/Janssen Biotech/Tibotec {38J/Centocor Ortho Biotech/Tibotec {38J/Ortho Biotech/Tibotec}} Vertex	To provide access to telaprevir for patients who were randomized to the control group in the VX-950-TIDP24-C216 trial (referred to as C216 trial hereafter) and who failed therapy for virologic reasons. To evaluate the efficacy, safety, and tolerability of telaprevir in combination with Peg IFN alfa 2a and RBV. In addition, amino acid changes from baseline in the HCV NS3 [L [CONT.]	
4 Link	A Randomized, Parallel-Group, Dose-Ranging Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Antiviral Activity of VX-222 and Telaprevir in Combination With and Without Peginterferon-Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment-Naive Subjects With Genotype 1 Chronic Hepatitis C.	NCT01080222	Adis Clinical Trials Database	Peginterferon-alfa-2a Ribavirin Telaprevir VX-222	Vertex Pharmaceuticals	This dose-ranging trial aims to evaluate the efficacy, pharmacokinetics and tolerability of telaprevir + VX 222 [Vertex Pharmaceuticals], alone or combined with peginterferon alfa-2a + ribavirin, in treatment-naive patients with genotype 1 hepatitis C. The primary endpoint is the tolerability of the combination therapy.	

HER-2 Inhibitors 2008 (RDI, RDI, PP, TP, INT)		Acrobat - Chart and Records					
	Product	Database	Synonyms	Originator	Highest Phase	Commercial Intro	Structure
1 Link	211A1-SAPS-C6.5	Thomson Reuters Integrity Compounds		Fox Chase Cancer Center	Preclinical		
2 Link	2B-1	Thomson Scientific IdDb	monoclonal antibody, c-erbB-2 and CD16	Chiron Corp	No Development Reported	2B-1 is a bispecific murine monoclonal antibody against c-erbB-2 and CD16, which was under development by Chiron for the potential treatment of cancer [150548]. A phase I trial for the potential treatment of breast and colon cancer was completed; however, no development has been reported since.	
3 Link	AEE 788	Adis R&D Insight	AEE788 NVP AEE 788 NVP-AEE788	Novartis	Phase I	AEE 788 is an orally available anticancer agent that is being developed by Novartis in collaboration with the University of Texas M. D. Anderson Cancer Center, USA. This small molecule acts as a reversible inhibitor of multiple tyrosine kinases, including EGFR (Epidermal growth factor receptor), HER2 (human epidermal growth factor receptor 2) and VEGFR2 (Vascular endothelial growth factor receptor 2) [CONT.]	
4 Link	AEE-788	Thomson Reuters Integrity Compounds	NVP-AEE-788	Novartis	Phase I/II	AEE-788 is an angiogenesis inhibitor in phase I trials at Novartis for the oral treatment of solid tumors. Early clinical studies have been completed by the company for the treatment of glioblastoma multiforme. Additional trials had been under way in patients with advanced colorectal cancer with liver metastasis, however, no recent development has been reported. [CONT.]	

Reports with images

When you export your BizInt Smart Charts report to Word, Acrobat, HTML and Excel, a .htm file is created along with an .img directory with a set of .jpg images files. These linked images can cause problems when distributing reports via email.

Good options for emailing reports with images:

Word - chart and records, or chart only

Before emailing a Word report, *you must embed the images in the .doc file* or the recipient will see broken links.

To embed the images in your Word file:

1. In Word 2003, select Edit | Links...
In Word 2007/2010, select the Prepare | Edit Links to Files option under the Office button (keyboard shortcut is Alt-E-K)
2. A Links panel will appear showing all the linked image files.
3. Select all the items in the list. You can select the first image, hold down the Shift key, and scroll to the bottom of list and select the last item.
4. Check the "Save picture in document" box at the bottom of the panel, and click OK.
5. Save the Word file (using Save As...) and verify that the file type is .doc.

Check the size of your .doc file before saving images. The size of the .doc file should increase significantly after the images are saved.

Acrobat - chart and records, or chart only

Adobe Acrobat automatically embed the images in your PDF file. This format is a good option for distributing reports with images.

Bad options for emailing reports with images:

- **Excel:** linked images cannot be embedded in an Excel spreadsheet, so there is no method to avoid broken links.
- **HTML:** linked images cannot be embedded in an HTML file, so there is no method to avoid broken links.

Word - chart and records, or chart only

These Word export formats are a good choice for creating a single file containing the table, record and images. It has the additional advantage of allowing you to edit the contents of the table and records.

Microsoft Word converts HTML table exported by BizInt Smart Charts to a Word table. Word tables must fit the width of a single page, so be careful exporting reports with many columns.

If you export the records, they are placed in the .doc file after the table. You can follow links from the drug name, patent title, or trial title column to the associated record (see top right image on page 1). Highlighting, shading, and other links will be preserved in your Word table.

Before emailing a Word report, *you must embed the images in the .doc file* or the recipient will see broken links – see instructions at left.



Acrobat - chart and records, or chart only

Adobe Acrobat (not Adobe Reader) converts the exported HTML to a PDF (see bottom right image on page 1). Links are converted to Acrobat bookmarks and the chart, records and images can all be included in a single file. Images are automatically embedded when you save the PDF file. Acrobat will scale large reports to fit and has excellent printing capabilities.

The drawback of the Acrobat PDF export format is that PDF's are not easily edited.

HTML Export Options

The HTML options panel appears for all HTML-based exports.

Under the Page section, you can add a link to the top of your HTML page, and specify which stylesheet to choose.

Under the Chart section, you have a number of options for the table appearance. For example, you can include a link to the publisher website under the row number in your exported report.

Under Records section, you can specify if records should be included in the HTML report, and if images should be included in the records.

Linking to Related Information in HTML Exports

You can use your exported report as a “portal” to related information, as shown below.

Links to Publisher Website

You can include an optional link to the related record on the publisher website.

Patents related to Cancer and Alzheimer's Treatment

Link to PDF version (use for printing)

	Title	Database	Patent Family	Patent Kind	Date	Graphic Information	Abstract
1	Use of hymenialdsine or its derivatives for inhibiting cyclin dependent kinases, GSK-3beta and casein kinase 1.	Derwent World Patents Index	EP 1106180 WO 2001041768 AU 2001023657 EP 1235578 US 2003105075 EP 1106180	A1 A2 A A2 A1 B1	20010613 20010614 20010618 20020904 20030605 20031112		Use of hymenialdsine (I) or its derivatives or salts for inhibiting cyclin dependent kinases, GSK-3 beta and casein kinase 1. Use of hymenialdsine of formula (I) or its derivatives or salts for inhibiting cyclin dependent kinases, GSK-3 beta and casein kinase 1. R1, R2 = H or Br.
2	USE OF PYRAZOLO [3,4-b] PYRIDINE AS CYCLIN DEPENDENT KINASE INHIBITORS	MicroPatent INPADOC	WO 9930710	A1	19990624		The compounds of formula (I) are proteinkinase inhibitors and are useful in the treatment and prevention of proliferative diseases, for example, cancer, inflammation and arthritis. They may also be useful in the treatment of neurodegenerative diseases such as Alzheimer's disease, cardiovascular diseases, viral diseases and fungal diseases.
3	Use of hymenialdsine or a derivative thereof as an inhibitor of cyclin-dependent kinases, GSK-3 and casein kinase 1, and therapeutic use	Chemical Abstracts	EP 1106180 EP 1106180 WO 2001041768 WO 2001041768 WO 2001041768 EP 1235578 JP 2004500356 US 2003105075	A1 B1 A2 A3 C2 A2 T2 A1	20010613 20031112 20010614 20020510 20020912 20020904 20040108 20030605		The title compds. are 1 (R1, R2 = H, Br), or a pharmaceutically acceptable salt thereof, are used for the manufacture of a medicament for inhibiting cyclin-dependent kinases, GSK-3, and casein kinase 1. The compds. may be used for preventing and treating neurodegenerative disorders (e.g. Alzheimer's disease), diabetes, inflammatory pathologies, and cancers.
4	Kinase Wee1 fusion protein compositions, nucleotide sequences, expression systems, and methods of use	US Patents Fulltext	US 2003216563	A1	20031120		The invention describes recombinant fusion proteins containing Wee1 protein sequences involved in checkpoint regulation of cell cycle, nucleic acid molecules that encode the fusion protein, and methods using the proteins for screening compounds which modulate Cdk1 function. GSK-3beta is AVAILABLE FOR THIS PATENT
5	New purine and aza-deaza analogues useful as cyclin dependent kinase inhibitors and antiviral, antimitotic, antiproliferative, immunomodulating, immunosuppressive, antiinflammatory, antimicrobial and/or antitumor agents.	Derwent World Patents Index	WO 2001049688 AU 2001035401 EP 1244668 NO 2002008247 CZ 2002008247 JP 2002008247 US 2002008247	A1 A A1 A A A	20010712 20010716 20021002 20020909		Purine and related aza-deaza analogues (I) and their salts are new.

2 Link

Kinase Wee1 fusion protein compositions, nucleotide sequences, expression systems, and methods of use

US Full

Patent Full-text Link Options

Choose how patent numbers from the following authorities should be converted to full-text links in HTML exports.

Authority Link to:

- US USPTO
- EP esp@cenet
- WO Patentscope
- FR.GB Micropatent, PatBase Express, PatentOrder, PatentOrder Direct, Patentscope, Thomson Innovation

OK, Cancel, Help, Configure

Patents related to Ca
Link to PDF version (use for printing)

Add a link to top of the HTML report

You can add a link to any file when you create your HTML report, using the “Include Link (after title)” option on the HTML export dialog.

Links to Full Patents

Links can be automatically generated from patent numbers to patents on government and commercial websites.

Links to Records in HTML file

Patent titles or drug names are linked to the records which appear below the table.

Using Styles and Style Sheets

The presentation of a chart and the associated records in HTML can be changed using the Styles option on the HTML Export panel. Several styles are provided. If the HTML will be viewed in a web browser we recommend using the “BizInt Modern Scaled” style (shown above), which attempts to scale the table to fit the width of the browser window.

If you know how to edit style sheets (CSS files) you can create your own styles by copying and modifying the existing style sheets. The style sheets are files with a .CSS extension, which can be found in the “css” folder where BizInt Smart Charts is installed. The name of the file is the name that will appear in the styles list.



Excel - Optimized HTML (chart only)

The new “Excel - Optimized HTML” export preserves most formatting while creating only one row in Excel for each row in BizInt Smart Charts. This format is suitable for both distribution and further processing in Excel. However, this format has several limitations. Only the first link in a cell can be displayed and the entire cell will be linked. Records cannot be included in this format. Images will “float” on top of the spreadsheet.

Mousetraps 2005-2007 (DWPI, MP, PatBase, TP, Orbit, Innov)					
	Title	Database	Patent Assignee	Patent Family (Patent : Kid : Date)	Abstract
1	Mousetrap	PatBase	RECKITT BENCKISER AU PTY LTD RECKITT BENCKISER UK LTD RODGERS BRENDYN MURRAY WATSON DUNCAN MCLEOD WEST JEFFREY	GB 200325446 : A0 : 2003-12-03 AU 2004292376 : AA : 2005-06-09 WO 05051079 : A1 : 2005-06-09 EP 1691603 : A1 : 2006-08-23 KR 2006110287 : A : 2006-10-24 BR 200416076 : A : 2007-01-02 US 2007017149 : A : 2007-01-25	Source: WO05051079A1 The present invention is directed to a mousetrap comprising: an enclosure comprised of a top a base and apertures located on each of the top and the base wherein the enclosure is in an open position upon substantial alignment of the apertures; and a trigger mechanism comprising a lever arrangement and a biasing means operably connected to the top and the base wherein the lever [...see record]

Excel - HTML (chart and records)

You can use the Excel - HTML format to deliver a formatted report with the table and linked records in Excel. You have the option to include records and images and multiple links are supported.

	Title	Database	Patent Assignee	Patent Family (Patent : Kid : Date)
1	Mousetrap	PatBase	RECKITT BENCKISER AU PTY LTD	GB 200325446 A0 12/3/2003
Link			RECKITT BENCKISER UK LTD RODGERS BRENDYN MURRAY WATSON DUNCAN MCLEOD WEST JEFFREY	AU 2004292376 AA 6/9/2005 WO 05051079 A1 6/9/2005 EP 1691603 A1 8/23/2006 KR 2006110287 A 10/24/2006 BR 200416076 A 1/2/2007 US 2007017149 A 1/25/2007

The significant drawback of this format is that the structure of the data is not preserved – a row in BizInt Smart Charts can easily become many rows in Excel (see the example above). This format is a poor choice for applications where the information needs to be sorted, analyzed, or manipulated.

Excel - CSV (chart only)

The CSV (Comma Separated Values) format exports the chart only to a .csv file and opens it in Excel. The data structure is preserved but most formatting is lost. This format is recommended for statistical analysis of a few fields of data, but is not recommended for presentation or report delivery. Records, images, and links cannot be included in the .csv export.

Questions or suggestions?

Please contact us at:

phone 1.714.289.1000 (8 am - 5 pm Pacific/California time)
email support@bizcharts.com
web www.bizcharts.com

Limitations of Excel for Report Distribution

Excel is a spreadsheet tool designed for analysis of numerical data. However, patent and drug pipeline records consist primarily of text and image data, with very few numeric fields.

As a result, Excel is not capable of representing many key features of BizInt Smart Charts reports.

Excel display limitations include:

- Subtables** (such as Patent Family or Drug Development Phase) cannot be displayed within a cell in Excel.
- Images** “float” on top of an Excel spreadsheet, do not move with the rest of row, and do not automatically resize.
- Records** cannot be properly formatted in the Excel file (each line becomes a separate Excel row).
- Links** are limited to a single HTML link within each cell in Excel.
- Large text fields** (e.g. abstracts) and multiple text values (e.g. assignees, indications) may not display properly.

We recommend that you evaluate other export formats (Word, Acrobat, HTML) before distributing reports in Excel.

Many of the BizInt Smart Charts features critical to combining and manipulating patent and pipeline data are not available once reports are exported to Excel, including:

- Changing the column selection requires copy/paste or re-exporting the report to Excel.
- Once exported to Excel, reports cannot be automatically updated or combined with other reports, and tools such as “Generate Common Drug Name” cannot be used.

For delivery of reports to “aggressive end-users” who wish to manipulate the data, consider using the BizInt Smart Charts Viewer.